A Study in People With Abnormal Fat Levels in the Blood
- Conditions
- Dyslipidemia
- Registration Number
- NCT00116519
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purposes of this study are to determine:
* The safety of the study medication and any side effects that might be associated with it;
* Whether the study medication can help patients with low levels of 'good' cholesterol (HDL-C) and high blood fats or triglycerides (TG);
* How much of the study medication should be given to patients;
* How the study medication compares to fenofibrate (Lofibra), a drug used for people with low levels of HDL-C and high levels of TG.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
- Men and women between 18 and 80 years of age
- People with abnormal fat levels in the blood (low HDL, high TG)
- People with diabetes
- People whose blood pressure is greater than 160/95 mm Hg, on or off blood pressure medicine
- People who have had frequent chest pain or unstable angina, a heart attack or a heart procedure, including stent placement, within the past 3 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Effects on HDL-C and Triglycerides after 12 weeks Safety after 12 weeks
- Secondary Outcome Measures
Name Time Method Effects on factors of metabolic syndrome after 12 weeks Effects on biomarkers of atherosclerosis after 12 weeks Effects on LDL-C after 12 weeks
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
🇺🇸Wenatchee, Washington, United States